IC-8 Apthera IOL New Enrollment Post Approval Study

Who May Qualify: - 22 years of age or older, any race and any gender; - Posterior capsule opacification (PCO) requiring treatment in the IC-8 Apthera IOL eye - Able to comprehend and have signed a statement of willing to sign a consent form; - Availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visits; - Clear intraocular media in both eyes; - Preoperative corneal astigmatism ≤1.5 D in the IC-8 Apthera IOL eye prior to IC-8 Apthera implantation; - Prior IC-8 Apthera IOL implantation in one eye and a monofocal/monofocal toric IOL in the other eye in accordance with the directions for use (DFU) for each IOL. Who Should NOT Join This Trial: - Pharmacologically dilated pupil size less than 7.0 mm in the IC-8 Apthera IOL eye; - Irregular astigmatism in either eye; - History of retinal disease; - Active or recurrent anterior segment pathology; - Presence of ocular abnormalities; - Diagnosis of dry eye in which patients are unable to maintain eye comfort or adequate vision even with dry eye treatment; - Previous corneal or intraocular surgery, except cataract surgery; - History of ocular trauma or ocular conditions expected to require retinal laser treatment or other surgical intervention; - Acute, chronic or uncontrolled systemic disease that would, in the opinion of the investigator, confound the outcomes of the study; - Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with hormonal fluctuation that could lead to refractive changes and dry eye; - Concurrent participation or participation in any clinical trial up to 30 days prior to the first visit in the study. - Subjects who plan to be traveling, relocating or otherwise unavailable to attend any of the visits Always talk to your doctor about whether this trial is right for you.